Northwest Biotherapeutics (OTCMKTS:NWBO) Announces Earnings Results

Key Points

• Northwest Biotherapeutics reported earnings of ($0.01) per share for the recent quarter, indicating continued financial challenges for the company.
• The stock price of NWBO increased by 0.8%, trading at $0.24, with a significant volume of 861,498 shares exchanged.
• Northwest Biotherapeutics specializes in developing personalized immune therapies for cancer, leveraging a technology platform called DCVax to stimulate the patient's immune system.

Northwest Biotherapeutics (OTCMKTS:NWBO - Get Free Report) posted its earnings results on Thursday. The biotechnology company reported ($0.01) earnings per share for the quarter, Zacks reports.

Northwest Biotherapeutics Trading Up 0.8%

NWBO stock traded up $0.00 during trading on Thursday, reaching $0.24. The stock had a trading volume of 861,498 shares, compared to its average volume of 2,511,210. Northwest Biotherapeutics has a 52 week low of $0.17 and a 52 week high of $0.48. The stock's 50 day moving average is $0.25 and its two-hundred day moving average is $0.26. The firm has a market cap of $352.04 million, a PE ratio of -3.39 and a beta of -1.14.

Northwest Biotherapeutics Company Profile

Northwest Biotherapeutics, Inc, a biotechnology company, develops personalized immune therapies for cancer in the United States and internationally. The company develops its products based on DCVax, a platform technology that uses activated dendritic cells to mobilize a patient's own immune system to attack cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.